JAK3 and cancer: Comparable results are observed with Non‐Hodgkin's lymphoma, in which activation of IL2Rγ—JAK3—STAT5 signaling pathway significantly promotes cancer progression while knockdown of IL2Rγ garners the same effect as Tofacitinib, a JAK inhibitor that effectively inhibits the activity of JAK1 and JAK3.26, 27